GOLDMAN SACHS GROUP INC - ATEA PHARMACEUTICALS INC ownership

ATEA PHARMACEUTICALS INC's ticker is AVIR and the CUSIP is 04683R106. A total of 133 filers reported holding ATEA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.3%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of ATEA PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$732,642
-12.4%
221,342
+6.9%
0.00%
Q1 2024$836,559
+19.9%
207,069
-9.5%
0.00%
Q4 2023$697,962
-10.9%
228,840
-12.3%
0.00%
Q3 2023$783,069
-31.5%
261,023
-14.6%
0.00%
Q2 2023$1,143,397
+21.9%
305,721
+9.2%
0.00%
Q1 2023$938,201
-19.8%
280,060
+15.1%
0.00%
Q4 2022$1,169,874
+85417.1%
243,217
+1.2%
0.00%
Q3 2022$1,368
-15.2%
240,384
+5.8%
0.00%
Q2 2022$1,613
-99.9%
227,220
+12.7%
0.00%
Q1 2022$1,456,000
-41.7%
201,693
-27.9%
0.00%
Q4 2021$2,499,000
-90.0%
279,568
-60.8%
0.00%
-100.0%
Q3 2021$25,006,000
+206.2%
713,225
+87.6%
0.01%
+150.0%
Q2 2021$8,167,000
-48.0%
380,224
+49.6%
0.00%
-50.0%
Q1 2021$15,696,000
+54.2%
254,188
+4.3%
0.00%
+33.3%
Q4 2020$10,179,000243,6410.00%
Other shareholders
ATEA PHARMACEUTICALS INC shareholders Q2 2023
NameSharesValueWeighting ↓
BML Capital Management, LLC 5,462,079$16,659,34112.62%
TANG CAPITAL MANAGEMENT LLC 4,076,741$12,434,0601.15%
Stonepine Capital Management, LLC 839,514$2,560,5181.11%
Bain Capital Life Sciences Investors, LLC 2,485,638$7,581,1960.73%
CM Management, LLC 270,000$823,5000.66%
EcoR1 Capital, LLC 6,995,861$21,337,3760.55%
Acuitas Investments, LLC 171,098$615,3730.32%
Newtyn Management, LLC 508,474$1,550,8460.30%
Diametric Capital, LP 161,524$492,6480.30%
Auour Investments LLC 177,000$670,8300.26%
View complete list of ATEA PHARMACEUTICALS INC shareholders